Plasmid DNA Manufacturing Market - Databook 2025 to 2034

The global plasmid DNA manufacturing market size surpassed USD 2,150 million in 2024 and is predicted to reach around USD 15,070 million by 2034, registering a CAGR of 21.5% from 2025 to 2034.

Highlights of the Plasmid DNA Manufacturing Market

• North America dominated the global plasmid DNA manufacturing market in 2024.
• Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
• By grade, the GMP-grade segment holds a dominant presence and is expected to grow at the fastest rate in the market during the forecast period.
• By development phase, the clinical therapeutics segment led the plasmid DNA manufacturing market in 2024.
• By development phase, the pre-clinical therapeutics segment is expected to grow at the fastest rate in the market during the forecast period.
• By application, the cell & gene therapy segment holds a dominant presence in the market during the forecast period.
• By application, the DNA vaccines segment is expected to grow at the fastest rate in the market during the forecast period.
• By disease, the cancer segment holds a dominant presence in the plasmid DNA manufacturing market during the forecast period.
• By disease, the infectious disease segment is expected to grow at the fastest rate in the market during the forecast period.

Industry Valuation and Growth Rate Projection

The plasmid DNA manufacturing market is an effective and rapidly increasing sector that plays a crucial role in genetic research and biotechnology. Plasmid DNA is a circular, double-stranded DNA molecule that replicates independently of chromosomal DNA. With its capability to be genetically engineered, plasmid DNA serves as a vital element in the generation of advanced therapy medicinal products (ATMPs) like nucleic acid vaccines and cell and gene therapy.

• In March 2024, Novel Bio disclosed the signing of an item development and scale-up agreement with Culture Biosciences to manufacture plasmid DNA. Novel Bio will stretch its fund to Culture Biosciences to fast-track the advancement of scalable fermentation procedures for their proprietary NBx Platform for plasmid DNA production.

Plasmid DNA Manufacturing Market: Stats and Figures

• In June 2023, the INADcure Foundation reported a manufacturing alliance with Charles River Laboratories, under which the latter will be in charge of manufacturing high-quality pDNA for phase I/II clinical trials of a gene therapy against Infantile Neuroaxonal Dystrophy.

Industry Leader Announcements

• Allen Guo, CEO of ProBio

Allen Guo, CEO of ProBio, said, “We understand pharmaceutical companies’ concerns about how many plasmid DNA manufacturers do not have predictable timelines, and we are committed to raising the bar for the industry, and we will deliver at the speed drug developers deserve.”

• Olaf Scholz, Chancellor of the Federal Republic of Germany

“Medical biotechnology is a key technology of the 21st century. The pandemic has proven Germany’s capability as a location for innovation and manufacturing of medicines. Germany and Europe are becoming more resilient by building local value chains. BioNTech’s investment is very good news,” said Olaf Scholz, Chancellor of the Federal Republic of Germany.

How AI Has Benefitted the Plasmid DNA Manufacturing Market

• AI developments provide an excellent possibility for drug discovery and design, eventually affecting humanity. Thus, it depends highly on machine learning (ML) and AI technology.
• Genetics is not different to this trend, as ML and AI are anticipated to have an effect on nearly every section of the human experience.
• AI has remarkably assisted in the treatment of numerous biomedical conditions, including genetic diseases. In both basic and applied gene research, deep learning is considered a greatly versatile branch of AI that covers autonomous feature extraction, is growingly exploited.
• AI has huge potency in the genetics sector, but its development in this section may be hindered in the future by a shortage of knowledge regarding the accompanying challenges that could mask any possible advantages for patients.

Recent Developments

• In April 2024, Charles River Laboratories reported the item manufacturing agreement with Axovia Therapeutics to produce high-quality gene of interest plasmid and thus extend fund for the development of Axovia’s gene therapies for ciliopathies, involving Bardet-Biedl Syndrome (BBS).

Geographical Insights

The plasmid DNA manufacturing market is experiencing significant growth, with North America maintaining its position as the dominant region while Europe emerges as the rapidly growing market. In the APAC region, China stands out as a driver of growth in the space.

North America

North America dominated the global market in 2024. It is the foundation of the recombinant DNA advisory committee by NIH to tailor scientific, legal, and ethical issues pertaining to the usage of rDNA techniques is taking part in a vital role in boosting the acceptance of these techniques. The significant role of the body is to analyze human gene transfer research.

Europe

Europe is experiencing rapid growth in the plasmid DNA manufacturing market during the forecast period. It is assigned to a rise in research support and the existence of major market players in this area. The number of biopharmaceutical firms is increasing in Europe, owing to growing investments.

China and APAC

Asia Pacific (APAC) is projected to be the fastest growing in the market during the forecast period. The existence of untapped opportunities, enhancing healthcare infrastructure, economic development, and favorable initiatives by the government and producers in the biotechnology field are some factors accounting for this fast growth. However, this region provides relatively low-cost operating and producing units for conducting research.

Competitive Landscape

• Company Name: Charles River Laboratories
• Year of Incorporation: 1947
• Headquarters: Wilmington, Massachusetts, United States

Charles River Laboratories International tackles fierce competition from both renowned players and emerging disruptions in the company. With a target on reliability, quality, and customer satisfaction, the firm constantly attempts to stay ahead of the curve and manage its position as a pacemaker in the sector of biopharmaceutical research and development.

• Company Name: Kaneka Corp.
• Year of Incorporation: 1949
• Headquarters: Washington, D.C., United States

Kaneka Corp is a chemical production firm. Its item offerings include caustic soda, polyvinyl chloride, hydrochloric acid, rigid PVC compounds, flexible polyvinyl chloride (PVC) compounds, paste PVC, chlorinated PVC, and flexible polyvinyl chloride (PVC) compounds. Its products include expandable plastics and products, functional plastics, foodstuffs products, electronic products, synthetic fibers, and life science products. Kaneka functions research laboratories including cell therapy laboratories and regenerative medicine, biotechnology research laboratories, material solutions new research engine, and others.

• Company Name: Danaher
• Year of Incorporation: 1984
• Headquarters: Washington, D.C., United States

Danaher Corp designs, produces, and markets medical items and services. It provides a broader range of testing instruments, life science research apparatus, medical diagnostic solutions, professional microscopes, genomic consumables, reagents and mass spectrometry, filtration and flow cytometry, centrifugation, genomics, lab automation, particle counting, and characterization businesses.

Table: Annual Revenue: Charles River Laboratories vs Kaneka Corp. vs Danaher Corporation 2021-24 (Millions of US$)